Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "CRDMO"

45 News Found

WuXi STA breaks ground for second manufacturing facility in US
News | August 19, 2022

WuXi STA breaks ground for second manufacturing facility in US

This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region

WuXi AppTec plans to build a new site in Singapore
News | July 24, 2022

WuXi AppTec plans to build a new site in Singapore

Better serving global partners and advancing healthcare innovation

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
Biotech | July 10, 2022

WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates

AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing

WuXi STA opens Oligonucleotide and Peptide manufacturing facility
News | July 08, 2022

WuXi STA opens Oligonucleotide and Peptide manufacturing facility

Site Enhances New Modality CRDMO Platform Capacity for Customers

CPC Scientific announces new California peptide API manufacturing facility
News | June 24, 2022

CPC Scientific announces new California peptide API manufacturing facility

The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity

Latest Stories

FDA nod to first oral single-dose treatment for gonorrhea

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer

Accenture invests in Ryght AI to revolutionize clinical trials

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging